Search results
Results from the WOW.Com Content Network
[81] [82] One of three children, Tharman is the son of Emeritus Professor K. Shanmugaratnam, [82] a medical scientist known as the "father of pathology in Singapore", who founded the Singapore Cancer Registry and led a number of international organisations related to cancer research and pathology. [83] [84] [85]
Cancer treatment centres in Singapore are generally located in both public and private hospitals. These units and medical centres specialise in the treatment of cancer . [1] Raffles Hospital; Parkway East Hospital - Parkway Cancer Centre; Gleneagles Hospital - Parkway Cancer Centre [2] Tan Tock Seng Hospital; Singapore General Hospital
Established in 1964, Singapore Cancer Society is a self-funded voluntary welfare organisation which is dedicated to minimize the impact of cancer in Singapore through the provision of cancer treatment subsidies, financial and welfare aid to needy cancer patients, home hospice care services for terminally-ill cancer patients, as well as rehabilitation support programs for recovering cancer ...
(Reuters) -AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates (ADCs), the Anglo ...
The Cali Cancer Registry (Registro Poblacional de Cancer de Cali in Spanish) started in 1962 as a research program of the Department of Pathology of the University of Valle School of Medicine in Cali, Colombia. [17] Currently, Cali Cancer Registry is recognized by the International Agency for Research on Cancer (IARC), an entity of WHO. [18]
1 January – Voco Singapore Orchard Hotel is officially opened. [citation needed]New rules capping cycling groups at 5 cyclists in single file or 10 cyclists in 2-abreast when on the roads take effect.
Overall global cancer incidence (2022) [1] Country Including NMSC Excluding NMSC Number Rate Number Rate Australia 212,332 462.5 151,529 322.4 New Zealand 38,157 427.3
Singapore's first publicly funded drug candidate, ETC-159, which was discovered and developed through a collaboration with Duke-NUS Graduate Medical School, advanced into Phase 1 clinical trials in July 2015. This drug targets a number of cancers, including colorectal, ovarian and pancreatic cancers, which contribute to a significant proportion ...